company background image
MEM logo

Memphasys CHIA:MEM Stock Report

Last Price

AU$0.006

Market Cap

AU$11.9m

7D

20.0%

1Y

-33.3%

Updated

02 May, 2025

Data

Company Financials

MEM Stock Overview

Develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. More details

MEM fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Memphasys Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Memphasys
Historical stock prices
Current Share PriceAU$0.006
52 Week HighAU$0.012
52 Week LowAU$0.004
Beta0.84
1 Month Change-25.00%
3 Month Change-14.29%
1 Year Change-33.33%
3 Year Change-89.66%
5 Year Change-90.16%
Change since IPO-96.36%

Recent News & Updates

Recent updates

Shareholder Returns

MEMAU Life SciencesAU Market
7D20.0%6.0%3.5%
1Y-33.3%-26.3%5.9%

Return vs Industry: MEM underperformed the Australian Life Sciences industry which returned -29.5% over the past year.

Return vs Market: MEM underperformed the Australian Market which returned 5.4% over the past year.

Price Volatility

Is MEM's price volatile compared to industry and market?
MEM volatility
MEM Average Weekly Movement34.5%
Life Sciences Industry Average Movement10.1%
Market Average Movement9.4%
10% most volatile stocks in AU Market16.7%
10% least volatile stocks in AU Market4.1%

Stable Share Price: MEM's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: MEM's weekly volatility has increased from 29% to 34% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006n/aDavid Aliwww.memphasys.com

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company primarily develops Felix, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid oxidative stress assay; and AI-Port.

Memphasys Limited Fundamentals Summary

How do Memphasys's earnings and revenue compare to its market cap?
MEM fundamental statistics
Market capAU$11.90m
Earnings (TTM)-AU$5.11m
Revenue (TTM)AU$1.07m

11.1x

P/S Ratio

-2.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MEM income statement (TTM)
RevenueAU$1.07m
Cost of RevenueAU$143.92k
Gross ProfitAU$930.61k
Other ExpensesAU$6.04m
Earnings-AU$5.11m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.0026
Gross Margin86.61%
Net Profit Margin-475.23%
Debt/Equity Ratio64.7%

How did MEM perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/02 10:04
End of Day Share Price 2025/05/02 00:00
Earnings2024/12/31
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Memphasys Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.